EMERYVILLE, Calif., April 5, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide® compounds for the topical treatment and prevention of infections, today announced it has launched its CEO Blog designed to provide Company perspectives on industry news and topics of interest in a timely fashion to financial advisors, investors and journalists. The Company’s first blog post can be accessed here: http://www.thechairmansblog.com/ron-najafi/2012-04/going-beyond-antibiotics/
